Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.51 |
| ▸ | CSF1R | P07333 | 8/20 | 0.51 |
| ▸ | FLT3 | P36888 | 5/20 | 0.51 |
| ▸ | PIM1 | P11309 | 6/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.49 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731130 | 0.86 | KDR (0.70) | KDRCSF1RFLT3KITCYP2D6 | |
| SCHEMBL1967379 | 0.82 | KDR (0.52) | KDRCSF1RFLT3PIM1PIM2 | |
| SCHEMBL1968092 | 0.82 | KDR (0.55) | KDRCSF1RFLT3PIM1PIM2 | |
| SCHEMBL1966045 | 0.80 | PIM1 (0.64) | PIM1PIM2 | |
| SCHEMBL1966171 | 0.77 | PIM1 (0.79) | KDRCSF1RPIM1PIM2 | |
| Hydrochloric Acid SCHEMBL1975274 | 0.77 | PIM1 (0.78) | KDRCSF1RPIM1PIM2 | |
| SCHEMBL1978257 | 0.74 | KDR (0.52) | KDRCSF1RFLT3PIM1PIM2 | |
| SCHEMBL1975295 | 0.73 | KDR (0.44) | KDRCSF1RFLT3PIM1PIM2 | |
| SCHEMBL5764754 | 0.72 | FGFR1 (0.41) | KDRCSF1RFLT3 | |
| SCHEMBL3331516 | 0.72 | KDR (0.48) | KDRCSF1RFLT3KITCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895550-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8557809-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110144100-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010022081-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045835-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | KDR 589/4885CSF1R 651/4885FLT3 54/4885 |
| US-20110144100-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM3, PIM2 | KDR 94/4885CSF1R 255/4885FLT3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.